WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced...
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative...
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc....
31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the prior year#12 ranking for market...
WEBCASTED PRESENTATION TO BE HELD WEDNESDAY, AUGUST 17THCINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company” or “Quipt”)...
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid...
- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva...
Lucira COVID-19 & Flu Test – the 99% Accurate At-Home Test for Covid and Flu The first and only at-home...
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data...
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD 2022 results on Friday 19th of...
- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - -...
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology...
Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and...
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized...
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
At-Home Testing Improves Diabetes Care & Control for Individuals, Providers & Payers Alike PURCHASE, NY, Aug. 10, 2022 (GLOBE NEWSWIRE)...
Blue Serenity (English) Optimi Health's, Blue Serenity psilocybin. Blue Serenity (English) Optimi Health's, Blue Serenity psilocybin. Blue Serenity Psilocybin Packaging...
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative ColitisSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora...